Zhitong Finance App News, ST Renfu (600079.SH) announced that the company's holding subsidiary, Yichang Renfu Pharmaceutical Co., Ltd. (“Yichang Renfu”, the company holds 80% of its shares) recently received the “Drug Clinical Trial Approval Notice” for midazolam nasal spray approved and issued by the State Drug Administration.

Midazolam is a short-acting benzodiazepine central nervous system inhibitor. The midazolam nasal spray approved for clinical trials is intended for acute treatment of intermittent and stereotypical frequent seizures (i.e. cluster seizures/acute repetitive seizures) in patients with epilepsy aged 12 and above.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.